Gonadotroph
adenomas comprise 15-40% of all
pituitary tumors, are usually non-functioning and are often large and invasive at presentation. Surgery is the first-choice treatment, but complete resection is not always achieved, leading to high recurrence rates. As gonadotroph
adenomas poorly respond to conventional pharmacological
therapies, novel treatment strategies are needed. Their identification has been hampered by our incomplete understanding of the molecular pathogenesis of these
tumors. Recently, we demonstrated that MENX-affected rats develop gonadotroph
adenomas closely resembling their human counterparts. To discover new genes/pathways involved in gonadotroph cells
tumorigenesis, we performed transcriptome profiling of rat
tumors versus normal pituitary.
Adenomas showed overrepresentation of genes involved in cell cycle, development, cell differentiation/proliferation, and lipid metabolism. Bioinformatic analysis identified downstream targets of the
transcription factor SF-1 as being up-regulated in rat (and human)
adenomas. Meta-analyses demonstrated remarkable similarities between gonadotroph
adenomas in rats and humans, and highlighted common dysregulated genes, several of which were not previously implicated in pituitary
tumorigenesis. Two such genes,
CYP11A1 and NUSAP1, were analyzed in 39 human gonadotroph
adenomas by qRT-PCR and found to be up-regulated in 77 and 95% of cases, respectively. Immunohistochemistry detected high P450scc (encoded by
CYP11A1) and NuSAP expression in 18 human gonadotroph
tumors. In vitro studies demonstrated for the first time that
Cyp11a1 is a target of SF-1 in gonadotroph cells and promotes proliferation/survival of rat
pituitary adenoma primary cells and cell lines. Our studies reveal clues about the molecular mechanisms driving rat and human gonadotroph
adenomas development, and may help identify previously unexplored
biomarkers for clinical use.